Eli Lilly: Hope for Recovery?
This big pharma company has introduced several new drugs in the past couple of years and spends heavily on research and development.
The elixir that the pharmaceutical companies have so far failed to come up with: One to cure ailing stock prices. Darlings of the 1980s and 1990s, these stocks have been sick puppies since the market's peak in early 2000.
Indianapolis-based Eli Lilly (LLY) certainly hasn't found the remedy. But it boasts more new and highly profitable medicines than its competitors, as well as one of the industry's most formidable drug pipelines, says Zacks Investment Research. "New products should drive above industry average growth over the next few years," Zacks analyst Jason Napodano says in a note to clients. "We think investors should establish positions in the shares before what we believe will be a very positive 2006."
The company has introduced several new drugs, all with big potential, in the past couple of years. They include Byetta for diabetes; Cialis, the long-lasting drug for erectile dysfunction; antidepressant Cymbalta; and Strattera for attention-deficit disorder.
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.

Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The company's strategy is clear: It tries to attract the industry's best scientists, and it spends roughly 20% of sales annually on research and development. That's more than most competitors spend.
Napodano is particularly enthusiastic about Cymbalta, which shows promise against treatment-resistant depression and anxiety. He thinks the drug will be "a major driver of growth over the next several years." Another mental health medication, antipsychotic Zyprexa, which accounted for 30% of sales last year, has been experiencing increasing competition from newer drugs. Napodano expects sales to continue to decline, but at a much slower rate than last year.
As new Lilly drugs experience higher sales, Napodano estimates that earnings will increase more than 10% a year over the next four years. That's after years of mostly single-digit earnings growth. Analysts surveyed by Zacks expect the company to earn $3.15 per share this year and $3.41 next year. That gives the stock, recently $59, a price-earnings ratio of 19 on this year's earnings estimate. It yields an above-average 2.7%.
--Steven Goldberg
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
-
Standard Deduction 2026 Amounts Are Here
Tax Breaks What is the standard deduction for your filing status in 2026?
-
New 2026 Tax Brackets Are Set: What to Know Now
Income Tax The IRS has adjusted federal income tax bracket ranges for the 2026 tax year to account for inflation. Here's what you need to know.
-
If You'd Put $1,000 Into Bank of America Stock 20 Years Ago, Here's What You'd Have Today
Bank of America stock has been a massive buy-and-hold bust.
-
If You'd Put $1,000 Into Oracle Stock 20 Years Ago, Here's What You'd Have Today
ORCL Oracle stock has been an outstanding buy-and-hold bet for decades.
-
How to Invest for Rising Data Integrity Risk
Amid a broad assault on venerable institutions, President Trump has targeted agencies responsible for data critical to markets. How should investors respond?
-
If You'd Put $1,000 Into Sherwin-Williams Stock 20 Years Ago, Here's What You'd Have Today
Sherwin-Williams stock has clobbered the broader market by a wide margin for a long time.
-
If You'd Put $1,000 Into UnitedHealth Group Stock 20 Years Ago, Here's What You'd Have Today
UNH stock was a massive market beater for ages — until it wasn't.
-
What Tariffs Mean for Your Sector Exposure
New, higher and changing tariffs will ripple through the economy and into share prices for many quarters to come.
-
How to Invest for Fall Rate Cuts by the Fed
The probability the Fed cuts interest rates by 25 basis points in October is now greater than 90%.
-
Are Buffett and Berkshire About to Bail on Kraft Heinz Stock?
Warren Buffett and Berkshire Hathaway own a lot of Kraft Heinz stock, so what happens when they decide to sell KHC?